This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Non-epithelial cancer of skin
  • /
  • Avelumab for the treatment of metastatic Merkel ce...

Avelumab for the treatment of metastatic Merkel cell carcinoma.

Read time: 1 mins
Published:30th Jun 2017
Author: Cordes LM, Gulley JL.
Source: Drugs of Today
Availability: Pay for access, or by subscription
Ref.:Drugs Today (Barc). 2017;53(7):377-383.

Avelumab is a promising new therapeutic agent for patients with metastatic Merkel cell carcinoma, a rare and aggressive type of neuroendocrine tumor of the skin.

Until the recent approval of avelumab (Bavencio), no therapies were approved by the U.S. Food and Drug Administration for the treatment of metastatic Merkel cell carcinoma. In a recent trial, avelumab, an anti-programmed death ligand-1 antibody, demonstrated an objective response in 28 of 88 patients (31.8% [95.9% CI, 21.9–43.1]) with advanced, chemotherapy-refractory Merkel cell carcinoma. Overall, avelumab was well tolerated at a dose of 10 mg/kg administered intravenously every 2 weeks. Serious treatment-related adverse events were reported in 5 patients (6%), but no grade 4 adverse events or treatment-related deaths were reported. Preliminary data evaluating avelumab in chemotherapy-naive patients is also encouraging.


Read abstract on library site

Access full article